Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.
Khaitov M RAleksandra NikonovaIgor ShilovskiyKsenia V KozhikhovaIlya A KofiadiLyudmila VishnyakovaAleksandr A NikolskiiPia GattingerValeria KovchinaEkaterina BarvinskaiaKirill YumashevValeriy SmirnovArtem V MaerleIvan KozlovArtem ShatilovAnastasiia TimofeevaSergey AndreevKoloskova O ONadezhda KuznetsovaDaria V VasinaMaria A NikiforovaSergei RybalkinIlya SergeevDmitriy TrofimovAlexander MartynovIgor BerzinVladimir A GushchinAleksey KovalchukSergei BorisevichRudolph ValentaRakhim KhaitovVeronica SkvortsovaPublished in: Allergy (2021)
Thus, we developed a therapeutic strategy for COVID-19 based on inhalation of a modified siRNA-peptide dendrimer formulation. The developed medication is intended for inhalation treatment of COVID-19 patients.